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j ourna l homepage: www.e lsev ie r .com/ locate / th romresEditorialCancer and thrombosis: a fresh look at an old storyIntroductionExactly 150 years ago, a French physician, Armand Trousseau pub-
lished hisﬁndings on the association between gastric cancer and throm-
bosis [1]. This paper, and that published by Bouillard in 1823, [2] are
now recognized as the earliest clinical descriptions on the association
between malignant diseases and hemostasis.
In the past decade, hundreds of studies have provided consider-
able evidence that in patients with cancer, blood coagulation is
shifted in the direction of a prothrombotic state. Cancer and its treat-
ments represent well-recognized risk factors for venous thrombo-
embolism (VTE) [3]. Apart from clinical risk factors, such as advanced
age, immobility, surgery, and others, there are tumor-related mecha-
nisms contributing to the prothrombotic diathesis in patients with can-
cer. At least three mechanisms are known by which tumor cells can
activate hemostasis: 1) by the production of procoagulant, ﬁbrinolytic,
and proaggregating factors, such as tissue factor (TF), cancer
procoagulant (CP), plasminogen activator inhibitors, ADP, and others;
2) by releasing proinﬂammatory and proangiogenic cytokines, such as
tumor necrosis factorα and interleukin 1β; and 3) by directly interacting
with host vascular and blood cells, such as endothelial cells, leukocytes,
and platelets through adhesion molecules [4]. A large body of work has
shown that tumor cells activate blood coagulation through an increased
expression of TF [5]. Upregulation of TF in cancer cells may be due to
tumor-speciﬁc oncogenic transformations or hypoxia. TF expressed by
vascular, stromal and inﬂammatory cells might also contribute to the
procoagulant effect of the tumor environment. TF can also be released
on TF-exposing extracellular vesicles in the circulation [6]. Although the
mechanism is not entirely clear yet, correlation of TF expression with a
hypercoagulable state and an increased incidence of VTE has been re-
vealed in experimental models and in certain tumor types, such as pan-
creatic cancer [6,7]. In addition to constitutive activation of the extrinsic
pathway, increased levels of coagulation factors V, VIII, IX and XI have
been shown to contribute to the prothrombotic state in patients with
cancer [8]. Another extensively studied tumor cell procoagulant is CP,
which is a cysteine protease that is capable of activating factor X indepen-
dently of factor VII [9]. CP has been found in extracts of neoplastic cells
and in cancer patients’ sera but not in extracts of normally differentiated
cells. In addition to the activation of the coagulation system, cancer cells
produce proteins that are involved in the regulation of ﬁbrinolysis.
These include the expression of plasminogen activators as well as
plasminogen activator inhibitors 1 and 2, leading to an imbalance
of ﬁbrinolysis [4]. Tumor cells are also involved in direct cell-cell in-
teractions leading to a prothrombotic condition. This includes the ac-
tivation of platelets and white blood cells through the release of
certain soluble mediators, proteases, or cytokines.http://dx.doi.org/10.1016/j.thromres.2015.04.028
0049-3848/© 2015 Elsevier Ltd. All rights reserved.More interestingly, it has been evident for decades that there is
a two-way interplay between coagulation and cancer, i.e., the
procoagulant environment brought about by malignant cells may
also promote cancer progression. Although signiﬁcant progress
has been made in this area, the role of various elements of hemo-
stasis in malignant disease progression and tumor angiogenesis re-
mains to be elucidated. This direction of research is fascinating; in
addition to enhancing our understanding of cancer progression and
regulation, it could ultimately lead to the discovery of innovative
anticancer therapies. In early phases of metastasis, thrombin, gen-
erated by TF initiates ﬁbrin deposition and the recruitment of
platelets. This process has proven to be important in increasing
the adhesive properties and survival of tumor cells [5]. The adhe-
sion of platelets to tumor cells plays a substantial role in tumor
growth and metastasis. Inhibition of various mechanisms mediat-
ing platelet adhesion to tumor cells results in a signiﬁcant inhibi-
tion of tumor dissemination in experimental animal models [10].
The complex anticoagulant mechanisms of the endothelium, in-
cluding endothelial cell protein C receptor, thrombomodulin and
heparan sulfate proteoglycan, and its impairment may also play a
role in tumor cell metastasis by regulating local thrombin levels
[11,12]. Thrombin signals to endothelial cells and platelets through
cleavage of protease activated receptors (PARs). Thus, thrombin af-
fects tumor growth and metastasis by many separate mechanisms:
by leading to ﬁbrin formation, acting on platelets and triggering tumor
and endothelial cell signaling [13]. In addition to thrombin, a broad
range of proteases acting on PARs have emerged as important regulators
of tumor progression and metastasis. These proteases, including factor
Xa, plasmin, activated protein C, matrix metalloproteinases, tissue kalli-
kreins, and membrane-type serine proteases have been implicated in
the regulation of tumor microenvironment and in the cellular cross-
talk associated with tumor progression [5,10].The Role of Fibrinogen-like Protein 2 (FGL-2)/ﬁbroleukin in Tumor
Development
In this issue of Thrombosis Research, Rabidazeh et al. elaborate on
the role of the procoagulant protein, ﬁbrinogen-like protein 2 (FGL-2)/
ﬁbroleukin in tumorigenesis [14]. FGL-2, a member of the ﬁbrinogen
family of proteins, is a transmembrane prothrombinase exerting serine
protease activity that is capable of converting prothrombin to thrombin
in the absence of factor VII or factor X [15]. FGL-2 has been shown to be
involved in angiogenesis and it was found to be overexpressed in tumor
cells [16,17]. The exact role of FGL-2 in tumor development however,
has not been fully elucidated yet. A recent study found that knockdown
of FGL-2 delayed tumor growth and angiogenesis in mice injected with
2 Editorialhuman hepatocellular carcinoma cell line [18]. The underlying mecha-
nism was hypothesized to be a result of FGL-2 induced generation of
thrombin, leading to thrombin-induced tumorigenesis. Detailed work
by Rabidazeh et al. in this issue, however, establishes that in a different
tumor cell line (human prostate carcinoma cells) FGL-2 exerts direct,
non-thrombin mediated angiogenic and tumorigenic activity. Using an
in vitro pro-angiogenesis assay the authors showed that FGL-2 is
involved in capillary sprouting that is not inhibited by hirudin,
whereas FGL-2 silencing completely inhibited blood vessel forma-
tion. The role of FGL-2 in tumorigenesis was further elucidated by
the authors in an in vivo mouse model of tumor development. Se-
vere combined immunodeﬁciency (SCID) mice were injected with
intact (wild type) or FGL-2-silenced human prostate carcinoma
cell line (PC-3) clones. Injections of PC-3 with intact FGL-2 induced
poorly differentiated carcinoma in all mice; malignant cells pene-
trated the muscle ﬁbers and metastasized to the lung. Conversely,
injection of FGL-2 silenced PC-3 clones induced tumor develop-
ment only in two-thirds of the mice, moreover, tumors were signif-
icantly smaller and less aggressive, with signiﬁcantly fewer blood
vessels. Immunohistochemical staining revealed clearly visible
FGL-2 protein in the tumor cells as well as ﬁbroblast growth
factor-2 (FGF-2). However, staining for thrombin was negative
indicating a thrombin independent mechanism. In the gene-array
experiments using PC-3 clones, FGF-2 was signiﬁcantly downregulated
by FGL-2 silencing, and this process was associated with a decrease in
activation and phosphorylation of ERK1/2. These ﬁndings conﬁrm pre-
vious reports suggesting that activation of FGF/FGF receptor signaling
is sufﬁcient to induce prostate cancer development in mouse models
[19]. Results are in line with previous ﬁndings that this pathway has a
well-established role in angiogenesis, wound healing and carcinogene-
sis [20].
The work by Rabidazeh et al provides new insight into the mecha-
nisms underlying the proangiogenic and protumorigenic activities of
FGL-2 and draws attention to a new tumor procoagulant that may
serve as a link between cancer and coagulation. The importance of this
topic merits further research that could serve as a basis of potential
new approach to anti-tumor therapies.
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